Form4insider filings, from the source

SEC Form 4 · accession 0001209191-16-093158

Lineage Cell Therapeutics, Inc. · LCTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Alfred D Kingsley
Officer — See Remarks · Director · 10% Owner
Period of report
Jan 20, 2016
Accepted (ET)
Jan 22, 2016 · 5:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Common Shares, no par valueF1,F2Jan 20, 2016S300,000$2.35D5,638,055D
Common Shares, no par valueholding———1,506,905IBy Greenbelt Corp.
Common Shares, no par valueholding———375,351IBy Greenway Partners, LP

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Option to Purchase Common SharesF3$3.57holding————Jun 30, 2020Common Shares50,00050,000D
Option to Purchase Common SharesF4$3.11holding————Jun 30, 2019Common Shares50,00050,000D
Option to Purchase Common SharesF5$4.13holding————Jun 30, 2018Common Shares50,00050,000D
Option to Purchase Common SharesF6$4.60holding————Jun 30, 2017Common Shares50,00050,000D
Option to Purchase Common SharesF7$5.13holding————Jun 30, 2016Common Shares50,00050,000D

Explanation of responses

Remarks

Mr. Kingsley is Executive Chairman of certain BioTime subsidiaries.